Monopar Therapeutics Inc. (MNPR) earnings
MNPR earnings moved a median of -2.84% by the close. Quarterly and annual MNPR reports and results, each read against the price at its own news timestamp. Back to the MNPR overview →
22 measured MNPR earnings events.
Where these MNPR earnings landedvs 18 measured MNPR earnings reactions
| Middle 50% of MNPR earnings reactions | -5.50% to -0.25% |
|---|---|
| Median reaction (to close) | -2.84% |
| Measured reactions | 18 |
Point-in-time · zero look-ahead
Half of the 18 MNPR earnings events with a measured close landed between -5.50% and -0.25%; 22% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Monopar Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +0.21% | -0.25% | |
| Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | — | -0.25% | |
| Form 10-Q Monopar Therapeutics For: Mar 31 | SEC filing · Form 10-Q | +1.60% | +1.62% | |
| Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | +2.02% | +2.63% | |
| Form 10-K/A Monopar Therapeutics For: Dec 31 | SEC filing · Form 10-K | +0.10% | -4.10% | |
| Form 10-K Monopar Therapeutics For: Dec 31 | SEC filing · Form 10-K | -0.83% | -2.82% | |
| Form 10-Q Monopar Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +0.43% | — | |
| Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments | Press release | +0.43% | — | |
| Form 10-Q Monopar Therapeutics For: Jun 30 | SEC filing · Form 10-Q | — | — | |
| Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments | Press release | — | — | |
| Form 10-Q Monopar Therapeutics For: Mar 31 | SEC filing · Form 10-Q | +0.89% | -3.65% | |
| Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments | Press release | +0.89% | -3.65% | |
| Form 10-K Monopar Therapeutics For: Dec 31 | SEC filing · Form 10-K | +0.00% | -5.97% | |
| Form 10-Q Monopar Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +2.44% | +2.93% | |
| Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments | Press release | +2.44% | +2.93% | |
| Form 10-Q Monopar Therapeutics For: Jun 30 | SEC filing · Form 10-Q | -3.25% | -7.94% | |
| Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments | Press release | -3.25% | -7.94% | |
| Form 10-Q Monopar Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -3.85% | -8.83% | |
| Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline | Press release | -3.85% | -8.83% | |
| Form 10-K Monopar Therapeutics For: Dec 31 | SEC filing · Form 10-K | +0.00% | -2.85% | |
| Form 10-Q Monopar Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -2.53% | |
| Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments | Press release | +0.00% | -2.53% |
Keep exploring
More MNPR: analyst actions → · SEC filings → · MNPR overview →